EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer

George Seed, Nick Beije, Wei Yuan, Claudia Bertan, Jane Goodall, Arian Lundberg, Matthew Tyler, Ines Figueiredo, Rita Pereira, Chloe Baker, Denisa Bogdan, Lewis Gallagher und 24 weitere

Cancer Cell · 2024-12 · 42 (12) · 2113-2123.e4

DOI: 10.1016/j.ccell.2024.10.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-12. Verfasst von George Seed und 35 weiteren Autor:innen. Beteiligte Einrichtung: The Institute of Cancer Research, London, UK. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Drug Resistance, Neoplasm, Prostatic Neoplasms, Castration-Resistant, BRCA2 Protein. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Wellcome Trust, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PARP inhibition (PARPi) has anti-tumor activity against castration-resistant prostate cancer (CRPC) with homologous recombination repair (HRR) defects. However, mechanisms underlying PARPi resistance are not fully understood. While acquired mutations restoring BRCA genes are well documented, their clinical relevance, frequency, and mechanism of generation remain unclear. Moreover, how resistance emerges in BRCA2 homozygously deleted (HomDel) CRPC is unknown. Evaluating samples from patients with metastatic CRPC treated in the TOPARP-B trial, we identify reversion mutations in most BRCA2/PALB2-mutated tumors (79%) by end of treatment. Among reversions mediated by frameshift deletions, 60% are flanked by DNA microhomologies, implicating POLQ-mediated repair. The number of reversions and time of their detection associate with radiological progression-free survival and overall survival (p < 0.01). For BRCA2 HomDels, selection for rare subclones without BRCA2-HomDel is observed following PARPi, confirmed by single circulating-tumor-cell genomics, biopsy fluorescence in situ hybridization (FISH), and RNAish. These data support the need for restored HRR function in PARPi resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsDrug Resistance, NeoplasmProstatic Neoplasms, Castration-ResistantBRCA2 ProteinHumansMaleMutationPhthalazines

Stichwörter der Autor:innen

DNA repairPARP inhibitioncfDNAgenomicsprostate cancerreversion

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA2 ProteinBRCA2 protein, humanPhthalazines

Autor:innen und Institutionen

  • The Institute of Cancer Research, London, UK.
  • The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
  • Heinrich Heine University, Düsseldorf, Germany.
  • The Royal Marsden NHS Foundation Trust, London, UK.
  • UCSF, San Francisco, CA, USA.
  • Vall d'Hebron Institute of Oncology, Barcelona, Spain.

Förderung

  • Cancer Research UK
  • Wellcome Trust
  • Medical Research Council
  • AstraZeneca
  • Royal Marsden NHS Foundation Trust
  • V Foundation
  • UK Research and Innovation Medical Research Council
  • CRIS Cancer Foundation

Zitieren

APA

Seed, G., Beije, N., Yuan, W., Bertan, C., Goodall, J., Lundberg, A., Tyler, M., Figueiredo, I., Pereira, R., Baker, C., Bogdan, D., Gallagher, L., Cieslik, J. P., Greening, S., Lambros, M., Neves, R., Magraner-Pardo, L., Fowler, G., Ebbs, B., …, & de Bono, J. (2024). Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell, 42(12), 2113-2123.e4. https://doi.org/10.1016/j.ccell.2024.10.015

Vancouver

Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, et al. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell. 2024;42(12):2113-2123.e4. doi:10.1016/j.ccell.2024.10.015

BibTeX
@article{Seed2024,
  author = {Seed, George and Beije, Nick and Yuan, Wei and Bertan, Claudia and Goodall, Jane and Lundberg, Arian and Tyler, Matthew and Figueiredo, Ines and Pereira, Rita and Baker, Chloe and Bogdan, Denisa and Gallagher, Lewis and Cieslik, Jan-Phillipp and Greening, Semini and Lambros, Maryou and Neves, Rui and Magraner-Pardo, Lorena and Fowler, Gemma and Ebbs, Berni and Miranda, Susana and Flohr, Penny and Bianchini, Diletta and Rescigno, Pasquale and Porta, Nuria and Hall, Emma and Gurel, Bora and Tunariu, Nina and Sharp, Adam and Pettit, Stephen and Stoecklein, Nikolas H and Sandhu, Shahneen and Quigley, David and Lord, Christopher J and Mateo, Joaquin and Carreira, Suzanne and de Bono, Johann},
  title = {Elucidating acquired PARP inhibitor resistance in advanced prostate cancer},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {12},
  pages = {2113--2123.e4},
  doi = {10.1016/j.ccell.2024.10.015}
}
Kostenlos starten →